Hologic, Inc. (NASDAQ:HOLX) saw a significant growth in short interest in November. As of November 29th, there was short interest totalling 6,820,000 shares, a growth of 94.3% from the November 14th total of 3,510,000 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average trading volume of 2,319,500 shares, the short-interest ratio is presently 2.9 days.
HOLX stock traded up $0.40 during trading on Wednesday, hitting $52.60. 1,910,312 shares of the company traded hands, compared to its average volume of 1,891,214. The company has a 50-day moving average of $49.19 and a 200-day moving average of $48.71. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.68. Hologic has a 1 year low of $37.48 and a 1 year high of $53.00. The firm has a market capitalization of $13.97 billion, a PE ratio of 21.65, a P/E/G ratio of 2.22 and a beta of 0.77.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.65. Hologic had a positive return on equity of 29.67% and a negative net margin of 1.19%. The business had revenue of $865.80 million for the quarter, compared to analysts’ expectations of $846.54 million. During the same period in the previous year, the firm earned $0.58 EPS. The business’s quarterly revenue was up 6.4% on a year-over-year basis. Sell-side analysts expect that Hologic will post 2.63 EPS for the current year.
Institutional investors have recently modified their holdings of the company. Nuveen Asset Management LLC raised its holdings in Hologic by 72,308.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock valued at $254,730,000 after buying an additional 5,297,332 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Hologic by 203.5% in the second quarter. Point72 Asset Management L.P. now owns 1,056,488 shares of the medical equipment provider’s stock valued at $50,733,000 after acquiring an additional 708,361 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Hologic by 22.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,960,574 shares of the medical equipment provider’s stock valued at $94,147,000 after acquiring an additional 363,053 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Hologic by 323.0% during the second quarter. AQR Capital Management LLC now owns 415,932 shares of the medical equipment provider’s stock valued at $19,973,000 after acquiring an additional 317,614 shares during the last quarter. Finally, Parnassus Investments CA raised its stake in shares of Hologic by 1.9% during the third quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock valued at $799,048,000 after acquiring an additional 300,090 shares during the last quarter. Hedge funds and other institutional investors own 94.07% of the company’s stock.
A number of research analysts have commented on HOLX shares. Argus increased their price target on shares of Hologic to $62.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. BidaskClub raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. ValuEngine upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. William Blair reaffirmed a “buy” rating on shares of Hologic in a research note on Thursday, November 21st. Finally, Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $51.84.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: What is the significance of a dead cat bounce?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.